Introduction {#s1}
============

The Wnt/β-catenin signaling cascade is an ancient cell communication pathway that operates context-dependent transcriptional switches to control animal development and tissue homeostasis ([@bib7]). Deregulation of the pathway in adult tissues can lead to many different cancers, most notably colorectal cancer ([@bib10]). Wnt-induced transcription is mediated by T cell factors (TCF1/3/4, LEF1) bound to Wnt-responsive enhancers, but their activity depends on the co-activator β-catenin (Armadillo in *Drosophila*), which is rapidly degraded in unstimulated cells. Absence of β-catenin thus defines the OFF state of these enhancers, which are silenced by Groucho/TLE co-repressors bound to TCF via their Q domain. This domain tetramerizes to promote transcriptional repression ([@bib8]), which leads to chromatin compaction ([@bib58]) apparently assisted by the interaction between Groucho/TLE and histone deacetylases (HDACs) ([@bib30]; [@bib67]).

Wnt signaling relieves this repression by blocking the degradation of β-catenin, which thus accumulates and binds to TCF, converting the Wnt-responsive enhancers into the ON state. This involves the binding of β-catenin to various transcriptional co-activators via its C-terminus, most notably to the CREB-binding protein (CBP) histone acetyltransferase or its p300 paralog ([@bib43]), resulting in the transcription of the linked Wnt target genes. Subsequent reversion to the OFF state (for example, by negative feedback from high Wnt signaling levels near Wnt-producing cells, or upon cessation of signaling) involves Groucho/TLE-dependent silencing, but also requires the Osa/ARID1 subunit of the BAF (also known as SWI/SNF) chromatin remodeling complex ([@bib11]) which binds to β-catenin through its BRG/BRM subunit ([@bib3]). Cancer genome sequencing has uncovered a widespread tumor suppressor role of the BAF complex, which guards against numerous cancers including colorectal cancer, with \>20% of all cancers exhibiting at least one inactivating mutation in one of its subunits, most notably in ARID1A ([@bib31]). Thus, it appears that failure of Wnt-inducible enhancers to respond to negative feedback imposed by the BAF complex strongly predisposes to cancer.

How β-catenin overcomes Groucho/TLE-dependent repression remains unclear, especially since β-catenin and TLE bind to TCF simultaneously ([@bib8]). Therefore, the simplest model envisaging competition between β-catenin and TLE cannot explain this switch, which implies that co-factors are required. One of these is Pygo, a chromatin reader binding to histone H3 tail methylated at lysine 4 (H3K4m) via its C-terminal PHD finger ([@bib18]). In *Drosophila* where Pygo was discovered as an essential co-factor for activated Armadillo, its main function appears to be to assist Armadillo in overcoming Groucho-dependent repression ([@bib39]). We recently discovered that Pygo associates with TCF enhancers via its highly conserved N-terminal NPF motif that binds directly to the ChiLS complex, composed of a dimer of Chip/LDB (LIM domain-binding protein) and a tetramer of SSDP (single-stranded DNA-binding protein, also known as SSBP). Notably, ChiLS also binds to other enhancer-bound NPF factors such as Osa/ARID1 and RUNX, and to the C-terminal WD40 domain of Groucho/TLE, and thus forms the core module of a multiprotein complex termed 'Wnt enhanceosome' ([@bib17]). We proposed that Pygo renders this complex Wnt-responsive by capturing Armadillo/β-catenin through the Legless adaptor (whose orthologs in humans are BCL9 and B9L, also known as BCL9-2) ([@bib33]; [@bib63]). The salient feature of our model is that the Wnt enhanceosome keeps TCF target genes repressed prior to Wnt signaling while at the same time priming them for subsequent Wnt induction, and for timely shut-down via negative feedback depending on Osa/ARID1 ([@bib17]).

Here, we assess the function of Legless and BCL9/B9L within the Wnt enhanceosome. Using a proximity-labeling proteomics approach (called BioID; [@bib54]) in human embryonic kidney (HEK293) cells, we uncovered a compelling association between BCL9/B9L and the core Wnt enhanceosome components, regardless of Wnt signaling. Co-immunoprecipitation (coIP) and in vitro binding assays based on Nuclear Magnetic Resonance (NMR) revealed that BCL9 and B9L associate with TLE3 through their C-termini, and that they bind directly to ChiLS via their evolutionary conserved homology domain 3 (HD3). These elements are outside the sequences mediating the adaptor function between Pygo and Armadillo/β-catenin, but they are similarly important for Wnt responses during *Drosophila* development and in human cells, as we show by CRISPR/Cas9-based genome editing. Our results consolidate and refine the Wnt enhanceosome model, indicating a constitutive scaffolding function of BCL9/B9L within this complex. Our evidence further suggests that BCL9/B9L but not Pygo undergoes a β-catenin-dependent rearrangement within the enhanceosome upon Wnt signaling, gaining proximity to TCF, which might trigger enhanceosome switching.

Results {#s2}
=======

The C-terminus of Legless is required for Wingless signaling during fly development {#s2-1}
-----------------------------------------------------------------------------------

Legless and BCL9/B9L paralogs (collectively referred to as Legless/BCL9 below) bind to Pygo and Armadillo/β-catenin via their conserved N-terminal homology domains 1 and 2 (HD1, HD2), respectively ([Figure 1A](#fig1){ref-type="fig"}). Previous evidence suggested that the sole function of Legless during *Drosophila* development is to link Pygo to Armadillo ([@bib33]). However, C-terminal truncations of BCL9/B9L behave as dominant-negatives regarding Wnt responses in mammalian cell lines ([@bib1]; [@bib15]), which suggested that their C-termini harbor functionally relevant elements. Indeed, these elements are missing in a Legless truncation encoded by a known *lgs* mutation (*lgs^7I^*), owing to a stop codon downstream of HD2 ([@bib33]), yet this truncation should be fully competent to link Pygo to Armadillo. Consistent with the notion of functional elements downstream of HD2, the C-termini of Legless/BCL9 exhibit several conserved sequence blocks, in particular HD3 ([Figure 1A](#fig1){ref-type="fig"}) which is found in all orthologs from the most primitive animals to humans. No ligand has been identified for HD3, nor for the C-terminus of Legless/BCL9.10.7554/eLife.20882.003Figure 1.The C-terminus of Legless is required for Wg-dependent patterns in flies.(**A**) Cartoon of *lgs* mutants, with domain boundaries indicated (*grey*, deleted sequences). (**B**) Western blot of lysates from *lgs* mutant embryos (genotypes indicated above panels), probed with antibodies as indicated, confirming stability of the *lgs^2-8^* truncation product (\~65 kDa, *arrowhead*; an unspecific cross-reactivity of this α-Lgs antiserum is marked by *asterisk*). (**C**) Developmental rates and survival of wt and *lgs* homozygous mutant larvae as indicated; first-instar larvae were picked (n = 25), and % pupation (*left*) or hatching of flies (*right*) was scored daily; error bars, SEM of four independent experiments. (**D**) Posterior leg and abdominal phenotypes of wt and *lgs* mutant flies, as indicated; representative examples are shown; *arrow*, missing sternite.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.003](10.7554/eLife.20882.003)10.7554/eLife.20882.004Figure 1---figure supplement 1.CRISPR/Cas9-based gene editing strategies for *Drosophila legless.*Cartoon of *lg*s exon boundaries and targeting sites in exon 4; sgRNA target sequences and PAM sites are highlighted in the wt sequence, with corresponding mutant sequences underneath; *red*, premature stop codons generated in *1-5 *and *2-8 *alleles.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.004](10.7554/eLife.20882.004)

To test the function of these sequences downstream of HD2, we deleted HD3 from endogenous *Drosophila lgs* (*lgs^ΔHD3^*) using the CRISPR/Cas9 system ([@bib50]). We also generated a truncation allele (*lgs^2-8^*) that deletes HD3 plus the entire C-terminus ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We isolated fly lines bearing these alleles, and confirmed that they express mutant proteins of the predicted sizes, and at normal levels ([Figure 1B](#fig1){ref-type="fig"}). Notably, the *lgs^2-8^* truncation allele causes pupal lethality if combined with a strong *lgs* allele (*lgs^20F^*; [@bib33]). Furthermore, homozygous *lgs^2-8^* animals (derived from homozygous mothers) show severely delayed development, and most die in their pupal cases, with \<25% of them hatching as flies ([Figure 1C](#fig1){ref-type="fig"}). A high fraction of these escapers exhibit patterning defects indicative of attenuated signaling by Wingless (Wg, *Drosophila* Wnt), as previously observed in flies bearing weak alleles of *lgs*, *pygo*, and *dTCF* ([@bib6]; [@bib33]; [@bib65])---namely proximal leg duplications and dorso-ventral polarity leg defects (in \~1/2 mutant flies) as well as loss of sternites in the ventral abdomen (in \~1/6 mutant flies; [Figure 1D](#fig1){ref-type="fig"}). Identical phenotypes were observed in homozygotes bearing an equivalent truncation allele isolated independently (*lgs^1-5^*; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), ruling them out as off-target effects of the CRISPR/Cas9 engineering process. Thus, the sequences downstream of HD2 are essential for *Drosophila* development, and appear to participate in Wg signaling responses.

To confirm this, we examined a Wg-responsive transcriptional enhancer from *dpp* (*dpp.lacZ*; [@bib5]), which is repressed by high levels of Wg signaling emanating from the Wg source in ventral compartments of leg discs via a homeodomain protein called Brinker ([@bib64]). Immunofluorescence revealed a striking derepression of *dpp.lacZ* in the ventral compartment of \>1/3 of the leg discs from *lgs^2-8^* homozygotes (28/78 discs) ([Figure 2A,B](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), demonstrating that the function of the mutant Legless in transducing the Wg signal is severely compromised in these discs. This was also true for wing discs (dissected from of pupating larvae, to ensure matched developmental timing between mutants and wild-type, wt): these discs exhibit much reduced expression of *Senseless* (*Sens*) (n = 50 discs; [Figure 2C,D](#fig2){ref-type="fig"}), a Wg target gene that specifies bristles along the wing margin and whose expression is abolished in *pygo* mutant clones ([@bib46]; [@bib18]). As expected, this attenuation of Sens results in fewer margin bristles in the homozygous mutant escaper flies (61 versus 80 stout margin bristles, and 15.6 versus 18.8 chemosensory bristles, per wt versus mutant wing, respectively), and larger gaps between individual stout bristles (22.7 versus 17.3 μm, per mutant versus wt wing, respectively) ([Figure 2E,F](#fig2){ref-type="fig"}; mean values from 10 wings dissected from different homozygous *lgs^2-8^* females; the sizes of wt and mutant wings were the same).10.7554/eLife.20882.005Figure 2.The C-terminus of Legless is required for nuclear Wg responses in imaginal discs.(**A, B**) Third leg discs from third instar (**A**) wt or (**B**) *lgs^2-8^*/*lgs^2-8^* larvae, fixed and stained with antibodies as indicated in panels (merges on the right), showing derepression of *dpp.lacZ* in the ventral compartment (arrow); space bar, 50 µm. (**C, D**) Corresponding wing discs, showing attenuated Sens expression along the prospective wing margin (see also insets); space bar, 100 µm. (**E, F**) Anterior margin segments of escaper flies, focused on stout margin bristles; *yellow arrows*, chemosensory bristles; *red arrows*, missing stout bristles causing gaps that are occupied by ectopic chemosensory bristles. (**G**) RT-qPCR assays of wing discs dissected from climbing wt and *lgs^2-8^*/*lgs^2-8^* third instar larvae, as indicated; values were normalized relative to *RpL32* (internal control), and are shown as mean ± SEM relative to wt (set to 1); \* = p\<0.05, \*\* = p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.005](10.7554/eLife.20882.005)10.7554/eLife.20882.006Figure 2---figure supplement 1.Additional analysis of *lgs^2-8 ^*during fly development.(**A**, **B**) Leg discs as in main [Figure 2](#fig2){ref-type="fig"} but giving rise to first or second leg, showing similar derepression of *dpp. LacZ *in the ventral compartments (*arrow*) of *lgs^2-8^/lgs^2-8^* homozygous larvae as seen in their third leg discs; space bar, 50 mm. (**C**) Stereo images of eyes from wt or heterozygous mutant females also expressing activated Armadillo (*F76*) ([@bib21]), as indicated in the panels, showing comparable suppression of the rough eye phenotype by *lgs^2-8^*/+ as by heterozygosity of the strongest known *lgs *allele (*lgs^20F^*; [@bib33]), or by a *pygo *null allele (*pygo^S123^*; [@bib65]).**DOI:** [http://dx.doi.org/10.7554/eLife.20882.006](10.7554/eLife.20882.006)

We also used RT-qPCR to examine RNA expression levels of the endogenous Wg target genes *engrailed*, *Distalless* and *H15* ([@bib7]; [@bib16]; [@bib75]) in lysates from wing discs dissected from climbing (that is, fully grown) homozygous *lgs^2-8^* larvae. We found significant reductions in the expression levels of all three target genes compared to controls ([Figure 2G](#fig2){ref-type="fig"}; note that neither *dpp* nor *dpp.lacZ* expression is controlled by Wg in wings discs; see [Figure 2C,D](#fig2){ref-type="fig"}). Finally, we also found that heterozygosity of *lgs^2-8^* suppresses the rough eye phenotype caused by activated Armadillo ([@bib21]), indistinguishably from heterozygosity of *pygo^S123^* or *lgs^20F^* ([@bib65]; [@bib33]) ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

These results demonstrate that the C-terminal Legless truncation encoded by our *lgs^2-8^* allele is severely compromised in its ability to transduce the Wg signal in multiple developmental contexts, despite retaining normal adaptor function in linking Pygo and Armadillo. Evidently, this adaptor function is not sufficient to sustain normal development if Legless is expressed at endogenous levels, suggesting that the previously reported rescue activities of equivalent Legless fragments ([@bib33]) may have stemmed from overexpression.

We also examined homozygous *lgs^ΔHD3^* animals, which hatched as flies without showing any developmental delay ([Figure 1C](#fig1){ref-type="fig"}). However, \~5% of these flies exhibited leg abnormalities, similarly to those exhibited by *lgs^2-8^* ([Figure 1D](#fig1){ref-type="fig"}) although the penetrance of this phenotype was much higher in the latter (see above). Nevertheless, these leg defects in the *lgs^ΔHD3^* homozygotes suggest that HD3 contributes to the function of Legless in transducing Wg responses.

The C-terminus of BCL9/B9L is required for Wnt responses in human cells {#s2-2}
-----------------------------------------------------------------------

Given these results from flies, we decided to also assess the function of the BCL9/B9L C-terminus and HD3 in the human Wnt response. We thus applied the CRISPR/Cas9 system to HEK293T cells ([@bib52]), to generate single knock-out (KO) cells lacking BCL9 or its nuclear paralog B9L, or double knock-out (DKO) cells lacking both ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Using a TCF-dependent reporter assay (called SuperTOP; [@bib70]), we found the Wnt-induced transcriptional activity of these DKO cells to be substantially reduced (to \<20% of their parental control cells; [Figure 3A](#fig3){ref-type="fig"}). Loss of BCL9 reduces the transcriptional activity nearly as much as loss of both paralogs, suggesting that BCL9 may be the physiologically limiting paralog in these cells, at least for transient Wnt responses. Likewise, the endogenous Wnt target genes *AXIN2* ([@bib37]) and *SP5* ([@bib28]; [@bib73]) are no longer Wnt-inducible in the DKO cells ([Figure 3B](#fig3){ref-type="fig"}), reconfirming the critical role of BCL9/B9L in the Wnt response of these cells.10.7554/eLife.20882.007Figure 3.The C-terminus of BCL9/B9L is required for transcriptional Wnt responses in human cells.(**A**) SuperTOP assays in wt or KO HEK293T cells lacking BCL9 and/or B9L, as indicated, ±6 hr of Wnt stimulation (WCM, Wnt3a-conditioned-media); mean ± SEM (n = 3 independent experiments). (**B**) RT-qPCR assays in wt or DKO HEK293T cells, ±6 hr of 20 mM NaCl or LiCl as indicated, revealing relative transcript levels of *AXIN2* or *SP5*; values were normalized to *TBP* (internal control), and are shown as mean ± SEM relative to unstimulated wt controls (set to 1); note that the uninduced levels of *SP5* were unusually high in one of the two DKO clones, but neither of the DKO clones showed Wnt-inducible *SP5*. (**C**) SuperTOP assays in wt or DKO HEK293T cells as in (**A**), 24 hr after transfection with wt and mutant B9L as indicated (*below*, corresponding Western blots; α-ABC, active unphosphorylated β-catenin); ev, empty vector control.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.007](10.7554/eLife.20882.007)10.7554/eLife.20882.008Figure 3---figure supplement 1.CRISPR/Cas9-based gene editing strategies for *BCL9* and *B9L* in HEK293T cells.(**A**) Cartoon of *BCL9* and *B9L *exon boundaries (with non-coding 5'-and-3'-UTR exons omitted); sgRNA targeting sites are marked for both genes. (**B**) sgRNA sequences, with PAM sites in bold. (**C**) Western blot of lysates from individual HEK293T clones with *BCL9* or *B9L* single KO, or with *BCL9/B9L *DKO, probed with antibodies as indicated on the left. (**D**) Summary of *BCL9/B9L *KO and DKO lines generated in this study.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.008](10.7554/eLife.20882.008)

When we re-expressed FLAG-B9L in the DKO cells, this restored full Wnt-responsiveness ([Figure 3C](#fig3){ref-type="fig"}). However, the C-terminal truncation mutants of B9L (△C, △HD3△C) failed to do so (despite elevated expression levels in the case of △HD3△C), and the HD3 deletion provided only partial rescue activity, similarly to a deletion mutant lacking the HD1 Pygo-binding element ([Figure 3C](#fig3){ref-type="fig"}). This demonstrates the crucial role of the B9L C-terminus for the Wnt response of these cells, and it indicates a functional contribution of HD3 to this response. Restoration of Wnt-responsiveness is also provided by re-expressed BCL9 tagged with green fluorescent protein (GFP-BCL9) albeit not by its C-terminal truncation, but we did not analyze this paralog further since its transcriptional activation potential is not as strong as that of the nuclear B9L ([@bib15]).

B9L and BCL9 are constitutively associated with the Wnt enhanceosome {#s2-3}
--------------------------------------------------------------------

Given the requirement of the BCL9/B9L C-terminus for the Wnt response, we set out to identify its ligands that confer this function. Since previous attempts based on tandem-affinity pull-down experiments were unsuccessful (M Graeb, PhD thesis), we adopted a proximity-labeling approach called BioID, tagging B9L and BCL9 with BirA\* (a promiscuous version of the biotin ligase BirA; [@bib54]) and using these as baits to probe the proteome associated with BCL9/B9L in cells. This method is capable of identifying transient low-affinity ligands of the bait as well as indirect bystanders (that is, indirect interactors and 'vicinal' proteins), provided these are within range of the BirA\* tag: in the case of Lamin A, \~50% of the hits were estimated to be within 20--30 nm of its BirA\* tag ([@bib54]). The upper limit appears to be \<100 nm, according to BioID studies with Cep250, an extended coiled-coil protein that spans \~100 nm within the centrosomal complex (as determined by super-resolution microscopy; [@bib62]): the C-terminal ligand of Cep250 was only labeled by its C-terminal but not its N-terminal BirA\* tag ([@bib20]). Therefore, the BioID approach can provide insight into the position and reach of a bait's BirA\* tag within a protein complex. Note that BCL9/B9L is presumed to be an extended protein, with \>90% of its sequence predicted to be intrinsically unstructured.

To keep the expression of our BCL9 and B9L baits near endogenous levels, we chose a tetracycline-controlled transcriptional activation system based on T-REx-293 cells ([@bib2]), isolating clonal T-REx-293 cell lines that express B9L-BirA\* and BCL9-BirA\* integrated at a specific genomic locus. Cells were labeled with biotin for 12 hr, with or without stimulation by Wnt3A-conditioned media or 50 mM LiCl (to inhibit glycogen synthase kinase 3, which causes activation of β-catenin, and thus mimics Wnt stimulation). Lysates were prepared for one-step biotin-avidin affinity purification and subsequent analysis by LC-MS/MS mass spectrometry. Recall that the probability of identifying a hit by this approach (reflected by the total number of unweighted spectral counts derived from this hit) is primarily determined by its proximity to the bait, but is also affected by the strength and duration of their interaction during the labeling period, and by other factors including size and cellular abundance of interactors and suitably exposed biotin-acceptor sites (primary amines).

We first conducted several experiments with B9L-BirA\* as a bait since the B9L paralog is predominantly nuclear, and thus likely dedicated to the transcriptional Wnt response, while BCL9 is distributed throughout the nucleus and cytoplasm ([@bib15]) ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), possibly carrying out additional functions in the cytoplasm such as chaperoning β-catenin ([@bib14]). Strikingly, each experiment identified known components of the Wnt enhanceosome, even in the absence of Wnt stimulation: we consistently found ARID1A and ARID1B as the top hits, followed closely by TLE3, TLE1, TLE4, LDB1 and PYGO2 and, further down the list, TCF factors, β-catenin and SSBP3/4 (initially named SSDP1/2; the peptides obtained do not distinguish between these closely related paralogs) ([Figure 4A](#fig4){ref-type="fig"}). We also found nine additional subunits of the BAF complex ([@bib31]) on our list, topped by BRG-1/SMARCA4, with only BAF155/SMARCC1, BAF47/SMARCB1, SS18 and BCL7 missing (the latter three likely for technical reasons; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). This indicates that the fully assembled BAF complex is tethered to the Wnt enhanceosome, presumably through its enhancer-binding Osa/ARID1 subunit which also binds to ChiLS (see Introduction). Furthermore, we found the CBP co-activator and its p300 paralog, as well as DNA-binding proteins of the LHX and GATA families known to tether ChiLS to DNA ([@bib36]). Essentially the same set of proteins were found with BCL9-BirA\* as a bait, albeit with lower efficiency ([Figure 4B](#fig4){ref-type="fig"}), possibly because of its largely cytoplasmic localization. Indeed, we found several cytoplasmic proteins specifically associated with BCL9 but not B9L, including α-catenin ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).10.7554/eLife.20882.009Figure 4.BCL9/B9L and PYGO2 are constitutively associated with the Wnt enhanceosome, and nuclear co-receptor complexes.(**A, B**) List of BioID hits for (**A**) B9L-BirA\* and (**B**) BCL9-BirA\*±10--12 hr of WCM; names above the dotted line refer to the top hits, while names below this line refer to hits selected on relevance to Wnt (blue) or nuclear co-receptors (green); only specific hits with a \> 5 spectral count ratio relative to the BirA\* control are shown; numbers represent unweighted spectral counts (\>95% probability). (**C**) RIME hits for FLAG-B9L-BirA\*; only specific hits with a \>5 spectral count ratio relative to the control are shown. (**D**) List of BioID hits for PYGO2-BirA\*, as in (**A, B**); \*, identified with lower confidence (\>55% probability).**DOI:** [http://dx.doi.org/10.7554/eLife.20882.009](10.7554/eLife.20882.009)10.7554/eLife.20882.010Figure 4---figure supplement 1.Stably transfected BCL9/B9L cell lines for BioID, and summary of wt and mutant BirA\* baits.(**A**) Immunofluorescence of stable BioID T-REx-293 cell lines expressing wt or mutant BCL9-BirA\*, B9L- BirA\* or BirA\* alone, showing subcellular distribution of the various baits; nuclei are labeled by DAPI staining. (**B**) Cartoons of wt and mutant BCL9-BirA\*, B9L-BirA\* and PYGO2-BirA\*. (**C**) Western blot probed with a-ABC antibody, to confirm Wnt induction of the stimulated PYGO2-BirA\* cell lysates prior to BioID pull-downs and analysis.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.010](10.7554/eLife.20882.010)10.7554/eLife.20882.011Figure 4---figure supplement 2.Additional analysis of BioID hits.(**A**) Venn diagrams, showing the number of hits shared between the BCL9, B9L and PYGO2 BioID baits with \>95% probability (excluding the BirA\*-only control);right, a selection of high-confidence BCL9-specific hits not found with the other two (nuclear) baits. (**B**) Components of the SWI/SNF complex found by all three baits.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.011](10.7554/eLife.20882.011)10.7554/eLife.20882.012Figure 4---figure supplement 3.Constitutive association between B9L and TCF prior to Wnt stimulation.CoIP assays in transiently transfected HEK293T cell, with Western blots showing (**A**) Wnt-independent association between GFP-TCF and FLAG-B9L, or (**B**) Wnt-dependent association between GFP-BCL9 with endogenous b-catenin or ABC (and Wnt-independent association with endogenous Pygo, as internal control). Transfected cells were exposed to LiCl, or NaCl as control, as described in the main Materials and methods.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.012](10.7554/eLife.20882.012)

To determine whether any of these hits might be direct ligands of B9L, we applied the RIME (rapid IP mass spectrometry of endogenous proteins) technique ([@bib41]) to our cell line stably expressing B9L-BirA\* at levels comparable to endogenous B9L, using FLAG resin to capture its N-terminal FLAG tag ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). This method relies on limited crosslinking of proteins in live cells followed by mass spectrometry of peptides cross-linked to the affinity-purified bait, and is thus capable of identifying direct ligands of the bait. It has been extensively validated for hit lists from immunoprecipitation-based approaches obtained for nuclear hormone receptors (for example, estrogen receptor) and other DNA-binding proteins ([@bib41]). These RIME experiments identified only five specific hits; these proteins associated with B9L-BirA\* ([Figure 4C](#fig4){ref-type="fig"}) include PYGO2, its only known direct ligand in the absence of Wnt. This short list also contained LDB1, which we shall identify below as another direct B9L ligand. It was topped by TLE3, suggesting that TLE3 may also be a direct ligand of B9L.

Importantly, the majority of the hits identified by B9L-BirA\* or BCL9-BirA\* hardly change after Wnt stimulation ([Figure 4A,B](#fig4){ref-type="fig"}). This implies that BCL9/B9L is associated with the Wnt enhanceosome prior to Wnt stimulation and independently of β-catenin. We note however that the spectral counts of many hits tend to be slightly increased upon Wnt signaling, a trend that is also apparent for TLE1 and TLE3 whose labeling by B9L-BirA\* was increased 2-3x upon Wnt stimulation ([Figure 4A,B](#fig4){ref-type="fig"}). Similarly, the labeling of GSE1 by B9L-BirA\* is increased 3-5x in stimulated cells ([Figure 4A](#fig4){ref-type="fig"}): GSE1 is a subunit of the BRAF-HDAC complex (also known as BHC) ([@bib25]), which might interact with Groucho/TLE through its HDAC subunit, potentially explaining the Wnt-dependent increase in the labeling of GSE1. In any case, TLE1/3 behaves like the LDB1 core component of the Wnt enhanceosome in remaining associated with Wnt-responsive enhancers even when these are active, consistent with recent findings that TLE1 and β-catenin can bind simultaneously to TCF1 ([@bib8]).

β-catenin triggers a Wnt-dependent apposition of the BCL9/B9L C-terminus to TCF {#s2-4}
-------------------------------------------------------------------------------

Association of β-catenin with BCL9/B9L is undetectable prior to Wnt stimulation, as expected from its low abundance in the absence of signaling. This may also explain why the labeling of CBP and p300 by B9L-BirA\* is stimulated \~4--6x upon Wnt stimulation, given that these histone acetyltransferases are known ligands of β-catenin. However, both proteins exhibit a significant level of labeling even without Wnt signaling, suggesting a constitutive association with the Wnt enhanceosome, consistent with the identification of CBP by RIME as a putative direct ligand of B9L. It thus appears that the binding of CBP and p300 to β-catenin upon its docking to the Wnt enhanceosome increases their proximity to the C-terminus of BCL9/B9L, which bears the BirA\* tag.

Three other factors exhibit a striking increase in labeling after Wnt stimulation, namely the TCF factors, APC and SSBP3/4 ([Figure 4A,B](#fig4){ref-type="fig"}). TCF4 is the only TCF paralog labeled prior to Wnt signaling, albeit at very low levels (also by the BirA\* control), but its labeling by B9L-BirA\* or BCL9-BirA\* is Wnt-inducible by 13x or 2.5x, respectively. For TCF1/3 and LEF1, no labeling is detectable in unstimulated cells, whereas each of these factors is labeled efficiently upon Wnt signaling (\>19--30x). The same is true for the APC tumor suppressor (\>29x), a BCL9-specific hit that is recruited to TCF target genes upon Wnt signaling by β-catenin ([@bib61]), owing to direct high-affinity binding ([@bib9]). Finally, the labeling of SSBP3/4 by B9L-BirA\* is moderately increased (\>6x) in Wnt-stimulated cells; as in the case of CBP/p300, SSBP3/4 is also detectable prior to Wnt signaling, albeit close to background levels. As far as we know, the expression levels of APC, SSBP3/4 and TCF factors do not change after Wnt stimulation, except for LEF1 whose levels increase \~2x in Wnt-stimulated HEK293T cells ([@bib13]). Therefore, a likely explanation for the Wnt-inducible labeling of these factors is that Wnt signaling, or β-catenin, induces their proximity to the C-terminus of BCL9/B9L. We note that TCF factors are bound constitutively to their cognate enhancers (for example, TCF4 in unstimulated HEK293 cells; [@bib22]) although, in *Drosophila*, the association of dTCF with Wg-responsive enhancers appears to be strengthened by Wg signaling ([@bib47]).

To obtain independent evidence for the constitutive association between BCL9/B9L and TCF, we conducted coIP assays in HEK293T cells co-expressing FLAG-B9L and GFP-TCF4. As expected, the two proteins coIP with similar efficiency in cells with or without Wnt stimulation ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Likewise, coIP of GFP-BCL9 with endogenous PYGO2 is also Wnt-independent, whereas its coIP with endogenous β-catenin (or activated β-catenin, ABC) is strictly Wnt-inducible, as expected ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). This underscores our notion that the Wnt-inducible labeling of TCF factors by B9L-BirA\* and BCL9-BirA\* reflects β-catenin-dependent apposition of the C-terminus of BCL9/B9L to TCF, rather than β-catenin-dependent recruitment of Legless/BCL9 to TCF (as initially envisaged; [@bib33]; [@bib63]).

The proximity of PYGO2 to TCF factors does not change during Wnt signaling {#s2-5}
--------------------------------------------------------------------------

Strong independent support for this notion came from BioID experiments with PYGO-BirA\*, which we expressed in T-REx-293 cells under identical conditions as the BCL9 and B9L baits; Wnt stimulation was confirmed by Western blotting against ABC ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). By and large, PYGO2-BirA\* identified the same Wnt enhanceosome components as B9L-BirA\*, with ARID1A/B topping the list ([Figure 4D](#fig4){ref-type="fig"}). Complete lists of specific BioID hits obtained with B9L-BirA\*, BCL9-BirA\* and PYGO2-BirA\* whose total number of unweighted spectral counts are ≥1, and 5x above background (that is, counts obtained for that hit with BirA\*), can be found in [Supplementary files 1](#SD1-data){ref-type="supplementary-material"}--[3](#SD3-data){ref-type="supplementary-material"}.

SSBP3/4 was labeled more efficiently by PYGO2-BirA\* than by B9L-BirA\*, consistent with our evidence that Pygo binds directly to an interface shared between LDB1 and SSDP ([@bib17]). Importantly, except for p300 and CBP whose labeling by PYGO2-BirA\* was moderately Wnt-inducible (\~3x), all other components of the Wnt enhanceosome and BAF complex were labeled with similar efficiency regardless of Wnt signaling, including TCF1/3/4 and LEF1 ([Figure 4D](#fig4){ref-type="fig"}). Thus, the proximity of PYGO2 to TCF factors does not change as a result of β-catenin docking the Wnt enhanceosome.

The C-terminus of BCL9/B9L mediates binding to TLE {#s2-6}
--------------------------------------------------

To identify ligands binding to HD3 or the C-terminus of BCL9/B9L, we applied BioID mass spectrometry to T-REx-293 cells stably transfected with mutant BCL9-BirA\* and B9L-BirA\* baits lacking these sequences (△HD3 and △C, respectively), and also with baits lacking HD1 (△HD1) expected to abrogate Pygo binding ([@bib18]). We confirmed that the subcellular distributions of these mutant BCL9-BirA\* and B9L-BirA\* baits were not affected by the various deletions ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

The lists of proteins associated with △C baits are similar to those found with the wt, but a few of them show reduced spectral counts, most notably in the case of BCL9ΔC which barely associates with TLE1 nor TLE3 ([Figure 5A](#fig5){ref-type="fig"}). coIP assays revealed robust binding between HA-tagged TLE3 (HA-TLE) and wt GFP-BCL9 but not with two different C-terminal truncations ([Figure 5B](#fig5){ref-type="fig"}). Indeed, the C-terminal WD40 domain of TLE3 is both necessary and sufficient for this coIP ([Figure 5C](#fig5){ref-type="fig"}). This domain binds to short motifs within a range of DNA-binding repressors ([@bib29]), but is not involved in binding to TCF ([@bib8]). Therefore, BCL9/B9L could bind directly to TCF-associated TLE/Groucho (as indicated by RIME, see above).10.7554/eLife.20882.013Figure 5.The Legless/BCL9 C-terminus binds to core Wnt enhanceosome components.(**A**) Top BioID hits showing differential association with wt versus mutant BCL9-BirA\* (unweighted spectral counts \> 95% probability). (**B, C**) Western blots of coIPs of wt or mutant GFP-BCL9 with (**B**) HA-TLE3 or (**C**) HA-tagged truncations, after co-expression in HEK293T cells (lysed 48 hr after transfection), probed with antibodies as indicated on the left. (**D**) Top differential BioID hits of B9L-BirA\* as in (**A**). (**E**) CoIP assays between co-expressed wt or mutant GFP-BCL9, LDB1-FLAG and SSDP-FLAG, as in (**B**); the band in the top panel corresponds to LDB1-FLAG.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.013](10.7554/eLife.20882.013)10.7554/eLife.20882.014Figure 5---figure supplement 1.HD3-dependent interaction between LDB1 and Legless/B9L.CoIP assays between co-expressed wt or mutant (**A**) GFP-B9L or (**B**) GFP-Lgs, and LDB1-FLAG and SSDP-FLAG, as in main [Figure 5E.](#fig5){ref-type="fig"}**DOI:** [http://dx.doi.org/10.7554/eLife.20882.014](10.7554/eLife.20882.014)10.7554/eLife.20882.015Figure 5---figure supplement 2.CRISPR/Cas9-based gene editing strategy for *PYGO2* in HEK293T cells.(**A**) Cartoon of *PYGO2 *exon boundaries and targeting site in exon 3; *top*, sgRNA sequence, with PAM site in bold; *underneath*, chromosomal location. (**B**) Western blot of lysates from individual HEK293T clones with *PYGO2 KO*, probed with antibodies as indicated on the left. (**C**) CoIP assays between co-expressed wt or mutant GFP-BCL9, and LDB1-FLAG plus SSDP-FLAG in wt or *PYGO2 KO* cells, confirming that the association of this BCL9 paralog with the ChiLS core complex is partly mediated by its binding to Pygo via HD1.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.015](10.7554/eLife.20882.015)

HD3 is a direct ligand of ChiLS {#s2-7}
-------------------------------

Likewise, a small number of proteins show reduced association with BCL9 or B9L baits lacking HD3, with the top hit being LDB1 whose association with B9L-BirA\* is reduced by half compared to the wt control ([Figure 5D](#fig5){ref-type="fig"}). Indeed, binding between LDB1-FLAG and GFP-B9L, GFP-BCL9 or GFP-Lgs is readily detectable in coIP assays, but is significantly reduced if HD3 is deleted ([Figure 5E](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Binding is similarly reduced by an alanine substitution of the most conserved residue in HD3 (W472 in BCL9, W520 in B9L; see also below), and eliminated if △HD1 is tested ([Figure 5E](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This indicates the importance of HD3 and HD1 for the interaction between ChiLS and BCL9/B9L, whereby HD1 likely contributes indirectly to this interaction via its binding to PYGO2 ([Figure 5A](#fig5){ref-type="fig"}) ([@bib18]). We generated PYGO2 KO cells by CRISPR/Cas9 (noting that HEK293T cells do not express PYGO1), to confirm that ChiLS coIPs less efficiently with BCL9 in the absence of Pygo ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). This supports the notion that Pygo promotes the association between BCL9/B9L and ChiLS.

Next, we asked whether HD3 is a direct binding site for ChiLS. This short conserved element is predicted to form a single α-helix ([@bib49]), with an invariant tryptophan and a phenylalanine/tyrosine (F/Y) doublet further downstream whose hydrophobic side chains extend in the same direction ([Figure 6A,B](#fig6){ref-type="fig"}). Together, they form a hydrophobic surface to which ChiLS may bind.10.7554/eLife.20882.016Figure 6.HD3 binds directly to ChiLS.(**A**) *Top*, sequence alignments of HD3; *yellow*, conserved residues; *grey*, semi-conserved residues. *Bottom*, position-specific alignment (HMMER; [@bib19]) for B9L HD3; *yellow*, conserved tryptophan and phenylalanine/tyrosine doublet. (**B**) Predicted structure of HD3 (by I-TASSER), with heat-map indicating relative line broadenings upon incubation of ^15^N-HD3 with ChiLS (see **D**), ranging from 80% (*red*) to 40% (*yellow*); *grey*, proline (not detectable). (**C**) TALOS+ predictions of α-helicity of HD3, based on backbone secondary chemical shifts in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}; for each position, the rigidity index (RCI-S^2^) and helical probability (**p**) are indicated (*pink*, N-terminal linker residues). (**D--F**) Overlays of HSQC spectra of 100 μM ^15^N-labeled (**D, E**) wt HD3 or (**F**) W520R mutant alone (*red*), and probed with 300 μM (**D, F**) MBP-Chip~205-436~-Lip-SSDP~1-92~ or (**E**) Lip-SSDP~1-92~ (*blue*); line broadening owing to ChiLS binding to wt HD3 (**D**) results in the disappearance of selected resonances in the blue (HD3 + ChiLS) spectrum, revealing the corresponding resonances from the red (HD3-only) spectrum.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.016](10.7554/eLife.20882.016)10.7554/eLife.20882.017Figure 6---figure supplement 1.Assignment of the \[^1^H-^15^N\]-HSQC spectrum of HD3.Assignments of ^1^H-^15^N correlations for the backbone amide resonances of \[^15^N-^13^C\]-Lip-HD3 residues, after overlay with \[^15^N-^13^C\]-Lip (to identify Lip residues).**DOI:** [http://dx.doi.org/10.7554/eLife.20882.017](10.7554/eLife.20882.017)10.7554/eLife.20882.018Figure 6---figure supplement 2.Modification of the *chip* phenotype by loss of HD3.(**A**) Genetic interactions between *chip*^e55^/+ heterozygosity (causing wing margin defects, marked by *arrowheads*) and heterozygosity of Wnt pathway components; representative wings are shown. Note that this phenotype is exacerbated by lowering the dose of SSDP protein (as expected, given that Chip and SSDP form an obligatory complex; see [@bib17]), but ameliorated by lowering the dose of associated proteins such as dTCF, Armadillo, Pygo, Legless or Groucho, possibly because normal levels of the latter sequester some of the limiting amounts of Chip (which is reduced in these heterozygotes). Note the strong suppression by the HD3 allele, possibly indicative of the direct binding of Chip to this domain. (**B**) Restoration of normal wing margins by heterozygosity of genes, as indicated (see also **A**); black, partial restoration (only anterior margin); *white*, restoration of both margins.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.018](10.7554/eLife.20882.018)

To test this, we purified ^15^N-labelled 6xHis-Lipoyl (Lip)-tagged B9L~509-537~ (Lip-HD3) after bacterial expression, for binding assays with purified ChiLS complex, as previously described ([@bib17]). ^15^N-Lip-HD3 proved soluble and monomeric (as judged by size exclusion chromatography), and produces well-dispersed heteronuclear single-quantum correlation (HSQC) spectra. Incubation of ^15^N-Lip-HD3 with purified ChiLS complex, but not with purified SSDP alone, produces clear line broadening ('bleaching') of selective peaks ([Figure 6D,E](#fig6){ref-type="fig"}) -- strong evidence for a direct interaction. Assignments of these peaks (obtained with a double-labeled ^13^C^15^N-Lip-HD3 sample; [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) provided experimental evidence for the helical nature of HD3 (as ascertained by TALOS+; [@bib59]) ([Figure 6C](#fig6){ref-type="fig"}). It allowed us to generate a heat-map that implicates most residues of HD3 in the interaction with ChiLS ([Figure 6B](#fig6){ref-type="fig"}). Importantly, no spectral changes are observed if a W520R-mutant version of ^15^N-Lip-HD3 is incubated with ChiLS ([Figure 6F](#fig6){ref-type="fig"}), showing that this point mutation abrogates the binding of HD3 to ChiLS. Thus, ChiLS binds directly and specifically to HD3.

Given this physical interaction between HD3 and ChiLS, we asked whether we could also detect genetic interactions between *lgs* and *chip* in *Drosophila*. Flies heterozygous for *chip* exhibit multiple wing notches ([@bib60]) that are strongly exacerbated by heterozygosity of *ssdp*; however, this phenotype is ameliorated by heterozygosity of several Wnt signaling components including *pygo*, *groucho* and *lgs* ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Interestingly, the strongest interaction is seen with *lgs^ΔHD3^* whose heterozygosity restores normal margins in \>25% of the flies. The same is also seen with *lgs^2-8^* heterozygosity although full suppression is less penetrant ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). These strong genetic interactions between *chip* and HD3-defective *lgs* alleles further underscore the close functional link between these two proteins.

The Wnt enhanceosome associates with nuclear co-receptor complexes {#s2-8}
------------------------------------------------------------------

Unexpectedly, we consistently found multiple components of nuclear co-receptors complexes amongst the top hits for all three BirA\* baits, including several NCOA co-activators and NCOR co-repressors ([Figure 4](#fig4){ref-type="fig"}). In the case of B9L-BirA\*, we also found the DNA-binding components of the resident complex, namely the arylhydrocarbon receptor (AHR) and its partner ARNT ([Figure 4A](#fig4){ref-type="fig"}). Clearly, there is close proximity between BCL9/B9L-PYGO2 and nuclear co-receptor complexes. This suggests that a substantial fraction of Wnt-responsive enhancers also contain binding sites for nuclear receptors (for example, AHR in HEK293T cells), and that these sites are near TCF-binding sites.

Discussion {#s3}
==========

Our study has uncovered genetic and physical interactions between two constitutive core components of the Wnt enhanceosome and the C-terminus of Legless/BCL9. The first of these is ChiLS, the core module of the Wnt enhanceosome ([@bib17]) ([Figure 7](#fig7){ref-type="fig"}): we have shown that ChiLS is a direct and specific ligand of the α-helical HD3 element of B9L and, likely, of other Legless/BCL9 orthologs, given the strong sequence conservation of this α-helix ([Figure 6](#fig6){ref-type="fig"}). The physiological relevance of this interaction with ChiLS is underscored by genetic analysis in flies. Our evidence thus implicates HD3 as an evolutionary conserved contact point between Legless/BCL9 and ChiLS, although the primary link between these two proteins appears to be provided by Pygo.10.7554/eLife.20882.019Figure 7.Refined model of the Wnt enhanceosome.The Wnt enhanceosome complex associated with a Wnt-responsive enhancer in its OFF or ON state (for initial model, see [@bib17], illustrating multivalent constitutive interactions of Legless/BCL9 with Pygo (through HD1), ChiLS (through HD3) and Groucho/TLE (through its C-terminus). *OFF*, HD2 is poised to interact with Armadillo/β-catenin upon Wnt-induced stabilization; *ON*, rearrangement of Legless/BCL9 upon recruitment of Armadillo/β-catenin, resulting in the apposition of its C-terminus to TCF. CBP/p300 is associated with both states (possibly through direct binding to Legless/BCL9); its activity may be directed towards histones upon Armadillo/β-catenin binding, which antagonizes Groucho/TLE-dependent silencing and promotes the transcription of linked target genes. Likewise, the BAF complex is associated with both states (through the NPF motif of its subunit Osa/ARID1), earmarking the complex for feedback inhibition (see [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). S, SSDP; Q, Q domain of TLE (tetramerizing, and binding to TCF); W, WD40 domain of TLE (binding to ChiLS); arrows, NPF-mediated interactions; green, positively-acting components; red, negatively-acting components; black circles, nucleosomes bearing H3K4me marks of poised or active enhancers ([@bib32]).**DOI:** [http://dx.doi.org/10.7554/eLife.20882.019](10.7554/eLife.20882.019)10.7554/eLife.20882.020Figure 7---figure supplement 1.Reinstalling silencing on a Wnt-responsive enhancer.Revised model for feedback inhibition of the Wnt enhanceosome in response to high signaling levels at the Wnt signaling source, which depends on the BAF complex and its Osa/ARID1 subunit (for initial model, see [@bib17]). The homeodomain protein Brinker has been implicated in this process by studies of the Wg-responsive *Ubx* midgut enhancer in flies, in which the Osa response element maps to the primary Brinker binding site ([@bib11]). Brinker confers repression of this enhancer in response to high Wg signaling levels by binding to the WD40 domain of Groucho, but its repressive activity also requires recruitment of its co-repressor Teashirt, whose expression is locally induced by high levels of signaling emanating from the Wg source ([@bib55]). Repression of the dpp leg enhancer near the Wg source in the ventral leg disc also depends on Brinker ([@bib64]). Notably, Teashirt binds to Armadillo ([@bib23]) and could thus compete with its binding to dCBP, suggesting a mechanism by which the Brinker-Teashirt complex may reinstall silencing on a Wnt-responsive enhancer. Note that the BAF complex might also be responsible for silencing the enhanceosome after cessation of Wnt signaling.**DOI:** [http://dx.doi.org/10.7554/eLife.20882.020](10.7554/eLife.20882.020)

A second link between the Legless/BCL9 C-terminus and the Wnt enhanceosome is mediated by the WD40 domain of TLE/Groucho. Given our evidence from RIME, this link is also likely to be direct although, for technical reasons, we have not been able to prove this. The function of the C-terminus of Legless/BCL9 for transducing Wnt signals was revealed by the *wg*-like phenotypes in *Drosophila* larvae and flies and by their defective transcriptional Wg responses ([Figure 1 and 2](#fig1){ref-type="fig"}), and by the loss of transcriptional Wnt responses in BCL9/B9L-deleted human cells ([Figure 3](#fig3){ref-type="fig"}). Our evidence indicates that Legless/BCL9 undergoes three separate functionally relevant interactions with distinct components of the Wnt enhanceosome---with Pygo, ChiLS and Groucho/TLE ([Figure 7](#fig7){ref-type="fig"}). Importantly, BioID revealed that these interactions are constitutive, preceding Wnt signaling, and that they hardly change upon Wnt stimulation ([Figure 4](#fig4){ref-type="fig"}). Taken together with its multivalent interactions with the Wnt enhanceosome, this is consistent with Legless/BCL9 being a core component of this complex, providing a scaffolding function that facilitates its assembly and/or maintains its cohesion.

Following Wnt stimulation, Legless/BCL9 undergoes an additional physiologically relevant interaction, by binding to (stabilized) Armadillo/β-catenin via HD2 ([@bib33]). Legless/BCL9 thus confers Wnt-responsiveness on the Wnt enhanceosome through its ability to capture Armadillo/β-catenin. In other words, in addition to scaffolding the enhanceosome, Legless/BCL9 also earmarks this complex for Wnt responses. Intriguingly, our BioID data indicated that the capture of β-catenin by Legless/BCL9 triggers its rearrangement within the complex, apposing its C-terminus to TCF ([Figure 7](#fig7){ref-type="fig"}). This apparent β-catenin-dependent apposition is consistent with structural data showing that BCL9/B9L HD2 is closely apposed to TCF when in a ternary complex with β-catenin ([@bib56]). Our evidence support the notion of Legless/BCL9 acting as an 'Armadillo loading factor', facilitating access of Armadillo/β-catenin to TCF ([@bib12]; [@bib66]), but argues against the original co-activator hypothesis which posited that Legless/BCL9 is recruited to TCF by Armadillo/β-catenin exclusively in Wnt-stimulated cells ([@bib33]; [@bib63]). Whatever the case, the β-catenin-dependent apposition of the Legless/BCL9 C-terminus to TCF is likely to trigger Wnt enhanceosome switching from OFF to ON, resulting in the relief of Groucho/TLE-dependent repression and culminating in the Wnt-dependent transcriptional activation of linked target genes ([Figure 7](#fig7){ref-type="fig"}).

This transition of the Wnt enhanceosome from OFF to ON is accompanied by a proximity gain between Legless/BCL9 and CBP/p300 ([Figure 4](#fig4){ref-type="fig"}), likely to reflect at least in part its de novo binding to Armadillo/β-catenin. However, our evidence indicates that CBP/p300 is associated with the Wnt enhanceosome prior to Wnt signaling, possibly via direct binding to B9L as suggested by RIME ([Figure 4C](#fig4){ref-type="fig"}), and that the docking of Armadillo/β-catenin to the Wnt enhanceosome strengthens its association with CBP/p300, and/or directs the histone acetyltransferase activity of CBP/p300 towards its substrates, primarily the histone tails. By acetylating these tails, CBP/p300 appears to promote Wnt-dependent transcription in flies and human cells ([@bib35]). Indeed, CBP-dependent histone acetylation has been observed at Wg target enhancers in *Drosophila* although, interestingly, this preceded transcriptional activation ([@bib47]). This is consistent with our BioID data, indicating constitutive association of CBP/p300 with the Wnt enhanceosome.

It seems plausible that histone acetylation at Wnt target enhancers is instrumental in antagonizing the compaction of their chromatin imposed by Groucho/TLE, which depends on its tetramerization via its Q domain ([@bib8]) as well as its binding to HDACs ([@bib30]; [@bib67]). Indeed, we found HDACs near the bottom of our BioID lists, and one of the top hits identified by B9L was GSE1, a subunit of the BRAF-HDAC complex ([@bib25]). However, CBP/p300 also has non-histone substrates within the Wnt enhanceosome, including dTCF in *Drosophila* whose Armadillo-binding site can be acetylated by dCBP, which thus blocks the binding between the two proteins ([@bib71]) and antagonizes Wg responses ([@bib35]). It thus regulates Wnt-dependent transcription positively as well as negatively, similarly to Groucho/TLE which not only silences Wnt target genes but also earmarks them for Wnt inducibility, as a core component of the Wnt enhanceosome. It is intriguing that both bimodal regulators are associated constitutively with this complex. A corollary is that the docking of Armadillo/β-catenin to the Wnt enhanceosome changes their substrate specificities and/or activities.

An important refinement of our initial enhanceosome model is with regard to the BAF complex, which appears to be a constitutive component of the Wnt enhanceosome ([Figure 7](#fig7){ref-type="fig"}), as indicated by our BioID data. This complex is highly conserved from yeast to humans, and it contains 15 subunits in human cells ([@bib31]), including the DNA-binding Osa/ARID1 subunit. A wealth of evidence from studies in flies and mammals indicates that this complex primarily antagonizes Polycomb-mediated silencing of genes, most notably of the *INK4A* locus which encodes an anti-proliferative factor, which could explain why the BAF complex functions as a tumor suppressor in many tissues. However, recall that this complex also specifically antagonizes Armadillo/β-catenin-mediated transcription ([@bib11]), likely via its BRG/BRM subunit which directly binds to β-catenin ([@bib3]). Evidence from studies in *Drosophila* of Wg-responsive enhancers suggests that this complex mediates a negative feedback from high Wg signaling levels near Wg-producing cells which results in re-repression ([@bib11]), imposed by the Brinker homeodomain repressor ([@bib55]; [@bib72]; [@bib64]) and its Armadillo-binding Teashirt co-repressor ([@bib23]) ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). The same factors may also instal silencing on Wnt-responsive enhancers upon cessation of Wnt signaling. Notably, mammals do not have a Brinker ortholog, which could explain some of the apparent functional differences between flies and mammals with regard to the BAF complex ([@bib31]). However, the closest mammalian relatives of Teashirt are the Homothorax/MEIS proteins, a family of homeodomain proteins whose expression can be Wnt-inducible (for example, [@bib74]). They are thus candidates for Wnt-induced repressors that confer BAF-dependent feedback inhibition.

Notably, none of our BioID lists contained RUNX proteins. Based on our functional evidence from *Drosophila* midgut enhancers, we proposed that these proteins (which bind to both enhancers and Groucho/TLE) are pivotal for initial assembly of the Wnt enhanceosome at Wnt-responsive enhancers during early embryonic development, or in uncommitted progenitor cells of specific cell lineages ([@bib17]). However, HEK293 cells are epithelial cells and may thus not express any RUNX factors. In any case, our negative BioID results suggest that RUNX factors function in a hit-and-run fashion. Evidently, the Wnt enhanceosome complex, once assembled at Wnt-responsive enhancers, can switch between ON and OFF states without RUNX.

In summary, we have uncovered a fundamental role to Legless/BCL9 as a scaffold of the Wnt enhanceosome, far beyond its role in linking Armadillo/β-catenin to Pygo. Indeed, the function of Legless/BCL9 may extend beyond transcriptional Wnt responses, as indicated by the unexpected discovery of its strong association with nuclear co-receptor complexes. Potentially, these associations underlie the observed cross-talk between Wnt/β-catenin and nuclear hormone receptor signaling, documented extensively in the literature (for example, [@bib4]; [@bib44]; [@bib57]), including evidence for direct activation of the androgen receptor by β-catenin ([@bib34]). Furthermore, a strong association between TLE1 and the estrogen receptor has been discovered in breast cancer cells, where TLE1 assists the estrogen receptor in its interaction with chromatin and its proliferation-promoting function ([@bib27]). This is reminiscent of the role of Groucho/TLE as a cornerstone of the Wnt enhanceosome, proposed to earmark TCF enhancers for subsequent β-catenin docking and transcriptional Wnt responses ([@bib17]). It will be interesting to test experimentally the putative roles of BCL9/B9L and Pygo in enabling cross-talk between β-catenin and nuclear hormone receptor signaling, both during normal development and in cancer.

Materials and methods {#s4}
=====================

Plasmids, antibodies and resins {#s4-1}
-------------------------------

The following plasmids have been described: LDB1-FLAG, SSDP-FLAG ([@bib17]); murine FLAG-B9L, FLAG-ΔC (called FLAG-ΔCter), GFP-B9L ([@bib1]); GFP-Lgs, GFP-TCF4 ([@bib66]). Human GFP-BCL9 was generated by exchanging the FLAG tag of FLAG-BCL9 ([@bib15]). Mutants were made from parental plasmids using standard site-directed mutagenesis procedures, and confirmed by sequencing. TLE3 was amplified by PCR from 6xMyc-TLE3 ([@bib26]) and subcloned in pcDNA3.1-N-HA, and mutants (WD40, ΔWD40) were generated from this subclone.

The following antibodies and resins were used: α-GFP RRID:[AB_439690](https://scicrunch.org/resolver/AB_439690), α-FLAG RRID:[AB_262044](https://scicrunch.org/resolver/AB_262044), α-HA RRID:[AB_390918](https://scicrunch.org/resolver/AB_390918), α-β-actin (for human lysates) RRID:[AB_476744](https://scicrunch.org/resolver/AB_476744) (Sigma-Aldrich, St. Louis MO, USA); α-BCL9 RRID:[AB_2063609](https://scicrunch.org/resolver/AB_2063609), α-BCL9-2 RRID:[AB_2063747](https://scicrunch.org/resolver/AB_2063747) (Abingdon, UK); α-β-actin (for fly lysates) RRID:[AB_2305186](https://scicrunch.org/resolver/AB_2305186), α-BirA RRID:[AB_300830](https://scicrunch.org/resolver/AB_300830), α-Pygo2 RRID:[AB_10863482](https://scicrunch.org/resolver/AB_10863482) (Abcam, Cambridge, UK); α-ABC RRID:[AB_11127203](https://scicrunch.org/resolver/AB_11127203) (Cell Signaling Technology). Rat α-Lgs antiserum (Eurogentec, Liège, Belgium) was obtained from pre-bleed immunizations with gluthathione S-transferase-purified Lgs~232-555~. GFP-Trap resin RRID:[AB_2631357](https://scicrunch.org/resolver/AB_2631357) (Chromotek, Planegg, Germany) was used for coIP assays, and α-FLAG M2 affinity gel RRID:[AB_10063035](https://scicrunch.org/resolver/AB_10063035) (Sigma-Aldrich) was used for RIME.

CRISPR/Cas9 genome editing in flies {#s4-2}
-----------------------------------

The CRISPR design tool at *crispr.mit.edu* was used to design single-stranded oligomers for sgRNA targeting vectors. pCFD3-1S and pCFD3-2S were generated by hybridizing single-stranded oligomers with their complementary strands in 2 mM Tris-HCl (pH 7.4), 10 mM NaCl, 200 μM EDTA at 95°C for 5 min, and by subsequently ligating the double-stranded oligomers into a *BbsI* restriction site of pCFD3 (kindly provided by Simon Bullock, MRC LMB, Cambridge, UK). pCFD4-HD3 was generated by inserting a double-stranded oligomer coding for sgRNAs targeting upstream and downstream of HD3 ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) into pCFD4 (from Simon Bullock) using Gibson assembly ([@bib24]).

Prior to injections into fly embryos (from a *vermilion* strain), pCFD3-1S, pCFD3-2S and pCFD4-HD3 were purified using plasmid midi kit columns (Qiagen, Venlo, Netherlands), and dissolved in injection buffer at 200 ng μl^−1^ containing 100 μM phosphate buffer and 5 mM KCl. Dechorionated embryos were injected by standard procedures, and sgRNA-expressing transgenic lines were identified on the basis of their *vermilion^+^* eye color, and subsequently crossed to a transgenic fly strain bearing *act5c.cas9* (from Simon Bullock), essentially as described ([@bib50], [@bib51]). For genotyping, DNA was extracted from individual flies by standard methods, and *lgs* sequences were determined after PCR amplification using the following primers: 5'-CATCGGGAAGAACAGTTGGC-3' and 5'-GGACTGGATGCAGCAAATCG-3' (for PCR amplification), and 5'-TGAATCAATTTCTTTTTCCTG-3' (for sequencing; see also below).

CRISPR/Cas9 genome editing in HEK293T cells {#s4-3}
-------------------------------------------

HEK293T cells were purchased from the European Collection of Cell Cultures (authenticated by STR DNA profiling). Upon receipt, cells were frozen, and individual aliquots were taken into culture, typically for analysis within \<10 passages. Single KO (of *BCL9*, *B9L*, or *PYGO2*) and *BCL9/B9L* DKO cells were generated essentially as described ([@bib52]), using guide RNA-encoding plasmid derivatives of pSpCas9(BB)−2A-GFP (PX458) obtained as described above for their fly equivalents ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}; [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Cells were sorted 48 hr post-transfection at a density of 1 cell/well in a 96-well plate and grown in Dulbecco's modified Eagles medium (supplemented with 10% fetal bovine serum, 100 U ml^−1^ penicillin, 100 µg ml^−1^ streptomycin) for 20--25 days to isolate individual clones. These were screened by genotyping (see below) and Western Blot analysis (for lack of BCL9, B9L or PYGO2 expression).

For genotyping, 2--5 × 10^4^ HEK293T cells were homogenized in 15 μl MicroLYSIS-Plus (Microzone, Haywards Heath, UK) and thermocycled as specified by the manufacturers. 2 μl supernatant was used for PCR amplification, and the resulting PCR products were purified using the QIAquick purification kit (Qiagen, Hilden, Germany) and sequenced. Sequence chromatograms were analyzed using MacVector software (MacVector Inc., Cary NC, USA). The following primers were used: 5'- CGAGATTTTCCTCTGGCAGC-3' and 5'-AAGGAGTCGGCGGAAATACT-3' (amplification of *BCL9*); 5'-GGATCCTGGCTAACAAGACAAG-3' and 5'-AGAAGTCCGACCACTCTGTG-3' (amplification of *B9L*); 5'-AGTCCAGAAAAGAAGCGAAGG-3' and 5'-CAGAAGCTTCAGTGGTCAGC-3' (amplification of *PYGO2*); 5'-ACCCACTTCCACAGCAGAG-3' (sequencing of *BCL9*); 5'- TGTCTGAGGAAGCCATGGAG-3' (sequencing of *B9L*); 5'-CTCGATCTCCTGACCTCGTG-3' (sequencing of *PYGO2*).

Fly strains and analysis {#s4-4}
------------------------

The following mutant *Drosophila* strains were used: *lgs^20F^*([@bib33]); *chip^e55^* ([@bib42]); *ssdp^L7^* ([@bib69]); *dTcf^3^* ([@bib68]); *arm^XM19 ^*([@bib48]); *gro^MB5^* ([@bib30]); *pygo^S123^* ([@bib65]). The strains for CRISPR-mediated genome engineering (*act5c.cas9*, *vermilion* bearing an *attP2* landing site) were provided by Simon Bullock (see also [@bib51]). Larvae were raised at 22°C for scoring of pupation, survival and mutant phenotypes; homozygous flies ([Figure 1](#fig1){ref-type="fig"}) were generated from homozygous mothers where possible (to eliminate maternal contributions). Preparation of wings, legs and abdomens were done according to standard protocols, and bright-field images were acquired with a Zeiss Axiophot microscope.

Wing and leg discs dissected from late third instar larvae (or pupating larvae if specified) were fixed with paraformaldehyde, and stained with α-Sens ([@bib45]), α-Wg RRID:[AB_528512](https://scicrunch.org/resolver/AB_528512) (Developmental Studies Hybridoma Bank) or chicken α-β-galactosidase RRID:[AB_2313752](https://scicrunch.org/resolver/AB_2313752) (Immune Systems, Paignton, UK) as described ([@bib17]; [@bib40]). All discs were counter-stained with DAPI, to control for the focal plane (though DAPI images are not shown in triple antibody stainings), and single confocal images were acquired at identical settings with a Zeiss Confocal Microscope. RNA was isolated from dissected wing discs with the RNeasy kit (Qiagen, Hilden, Germany) and converted to cDNA with Super RT (HTBiotechnology Ltd, Cambridge, UK). RT-qPCR reactions were subsequently run in Fast-96-well format on a Vii7 Real-Time PCR System (Applied Biosystems, Foster City CA, USA). The following TaqMan probes were used: Dm01792952_m1, Dm01820389_m1, Dm01804677_m1, Dm01842959_m1, Dm01803388_m1, Dm01843776_s1 and Dm02151827_g1 (Applied Biosystems, Foster City CA, USA). Statistical significance was assessed with two-tailed Student's t-tests.

Mass spectrometry {#s4-5}
-----------------

To generate BioID plasmids, BirA\*(R118G) was amplified from pcDNA3.1 mycBioID ([@bib54]) by PCR and subcloned into pcDNA5/FRT/TO using megaprimer PCR. Coding sequences for PYGO2, BCL9 and B9L (and mutants thereof) were amplified likewise and inserted directly upstream of BirA\* in pcDNA5/FRT/TO using Gibson assembly ([@bib24]). For each stably transfected BioID cell line, 1.4--2.1 × 10^8^ cells were grown adherent to full confluence, washed once with phosphate-buffered saline (PBS), flash-frozen in liquid nitrogen, and stored at −80°C for 1--20 days (for further details, see [@bib2]). BioID pull-downs were then essentially done as described ([@bib53]), and protein was eluted from the beads by boiling for 15 min in LDS sample buffer (ThermoScientific, San Jose CA, USA). RIME pull-downs were essentially done as described ([@bib41]), except that 3--5 × 10^7^ cells were washed in PBS and incubated for 6 min in 4% methanol-free formaldehyde (Polysciences, Warrington, USA) before lysis and boiling in sample buffer. All samples were resolved on 4--12% Bis-Tris polyacrylamide gels (Life Technologies, Carlsbad CA, USA), and gels were stained with Imperial Protein Stain (ThermoScientific, San Jose CA, USA). Gel slices (2--3 mm) were prepared for mass spectrometric analysis by manual in situ digestion with trypsin, and digests were analyzed by nano-scale capillary LC-MS/MS using an Ultimate U3000 HPLC (ThermoScientific Dionex, San Jose, USA). The analytical column outlet was directly interfaced via a nano-flow electrospray ionization source, with a hybrid dual pressure linear ion trap mass spectrometer (Orbitrap Velos, ThermoScientific, San Jose, USA). LC-MS/MS data were searched against a protein database (UniProt KB) using the Mascot search engine program (Matrix Science, London, UK). MS/MS data were validated using the Scaffold program (RRID:[SCR_014345](https://scicrunch.org/resolver/SCR_014345); Proteome Software Inc., Portland OR, USA), and processed with R (RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)).

Cell-based assays {#s4-6}
-----------------

HEK293T cells were cultured and transfected essentially as described ([@bib38]). For coIP assays, cells were lysed 48 hr post-transfection in lysis buffer (20 mM Tris--HCl pH 7.4, 10% v/v glycerol, 100 mM NaCl, 1 mM EDTA, 5 mM NaF, 2 mM Na~3~VO~4~, 0.2% v/v Triton-X-100) supplemented with protease inhibitors (Roche, Basel, Switzerland), and sonicated twice for 10 s with an amplitude of 15 μm using a Soniprep 150 plus (MSE, London, UK). Samples were cleared by centrifugation at 16,100 x g for 10 min, and supernatants were incubated with resin for 2 hr at 4°C. All inputs shown are equivalent to 10% of IPs.

For luciferase reporter assays, SuperTOP ([@bib70]) was co-transfected with CMV-Renilla as internal control, and assays were performed initially 48 hr post-transfection, but subsequently 24 hr post-transfection (for all figures shown in this study). Wnt inductions were for 6 hr (unless specified otherwise), either with Wnt3a-conditioned-media (WCM) or 20 mM LiCl (or 20 mM NaCl as control), and values of uninduced cells were set to 1.

RNA extractions, cDNA synthesis and RT-qPCR reactions were conducted as described above for fly wing discs. The following TaqMan probes were used: Hs00610344_m1, Hs01370227_mH and Hs00427620_m1 (Applied Biosystems, Foster City CA, USA).

Protein purification and NMR spectroscopy {#s4-7}
-----------------------------------------

The expression and purification of 6xHis-MBP-LDB1~56-285~, 6xHis-Lip-SSDP~1-92~ and 6xHis-Lip-HD3~509-537~ (from human B9L) as well as the acquisition and analysis of \[^1^H-^15^N\]fast-HSQC spectra were done as described ([@bib17], [@bib18]; [@bib40]). Spectra were acquired on a Bruker Avance-3 spectrometer operating at 600 MHz ^1^H frequency and with a sample temperature of 298 °K. All samples were prepared in aqueous phosphate buffer of physiological ionic strength (25 mM phosphate pH 6.7, 150 mM sodium chloride). Backbone resonance assignments were obtained for \[^13^C-^15^N\]-double-labelled Lip-HD3 using standard procedures ([@bib17], [@bib18]; [@bib40]).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Scaffolding of multiple Wnt enhanceosome components by BCL9/Legless\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by Robb Krumlauf as Reviewing Editor and Fiona Watt as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This paper presents interesting data that has the potential to help to resolve the mechanism of transcriptional activation of Wnt target genes. The manuscript addresses an important mechanistic detail of the TCF/b-catenin complex, concerning the addition of the ChiLS complex and how the Wnt \"enhanceosome\" may be assembled. The dominant model on TCF/b-catenin mediated transcription is the \"chain of co-activator\" model, which posits that TCF recruits β-catenin that in turn recruits the BCL9 and Pygo complex and other co-activators. The authors have challenged this model through a series studies, including the *eLife* 2015 paper, and they have argued that the BCL9, Pygo and the new ChiLS complex is preassembled on Wnt enhanceosome to recruit β-catenin. Understanding the mechanism concerning TCF/β-catenin is of general interest and important so the paper in principle is worthy of publication in *eLife*. However, there are a number of aspects of the work which need to be strengthened to make a compelling case. A few additional experiments should allow the authors to provide the supporting evidence to solidify this model and the authors need to modify the text and discussion around their model where the data are inconsistent. We realize it may take time to conduct the two main experiments suggested but we are willing to allow that time to strengthen this story.

The specific points to be addressed are:

1\) The authors do not discuss some inconsistencies of their data with current models of Wnt signaling. They need to provide a more comprehensive interpretation of their data and how it might be reconciled with their previous studies. If the C-terminal region of Bcl9 proteins functions by binding the repressor TLE, one would expect deleting this region to enhance basal expression of Wnt target genes, rather than reducing their activation by Wnt. Analysis of Wg target gene expression in the *lgs^2-8^* mutant might help to clarify this issue.

It is also not clear why the Chip heterozygous phenotype, which looks like a loss of wg function, should be suppressed by removing positively acting components of the complex such as *arm* and *lgs*, as well as the negatively acting component gro.

The absence of any Runx protein in the BCL9 and B9L biotinylation assays argues against such a protein being a central part of the Wnt enhanceosome as proposed by Fiedler et al.

The observation that Wnt signaling is necessary for the interaction of Lgs with β-catenin and TCF proteins and does not reduce its association with TLE proteins does not support a model in which the enhanceosome is present at TCF-bound enhancers in the absence of Wnt signaling.

2\) The Authors employed BioID (using BirA\*) followed by mass spectrometry to identify BCL9 (and the related B9L) binding partners (TLE, ChiLS, and nuclear receptor co-activators). They went one step further and combined BioID and spectral counting as a (semi) quantitative measurement for determination of protein interactions with and without Wnt. It is not clear to me whether these methods offer reliable quantification. For example, spectral counts for LDB1 and SSDP in [Figure 3D](#fig3){ref-type="fig"} appear to contradict the IP results in [Figure 3E](#fig3){ref-type="fig"}, in particular with regard to the HD1 deletion mutant. It would be highly desirable that additional approaches can back up these arguments (derived from BioID). One of the key arguments of the authors\' model is that Pygo/BCL9 and associated ChiLS are preassembled on chromatin prior to Wnt stimulation and recruits b-catenin to TCF upon Wnt signaling. The authors should demonstrate this important issue using other techniques, such as CHIP.

3\) The NMR results showed that HD3 directly interacts with LDB1/SSDP, and HD3 deletion and W472A mutants reduced BCL9-LDB1 coIP. But HD1 appeared to have a more critical role as its deletion completely abolished BCL9-LDB1 coIP. The authors suggested, reasonably, that HD1 binding to Pygo, which interacts with LDB1, has a critical role in this multivalent interaction. The authors should be able to demonstrate this point directly using Pygo knockdown or knockout (via CRISPR).

10.7554/eLife.20882.025

Author response

*Summary:*

This paper presents interesting data that has the potential to help to resolve the mechanism of transcriptional activation of Wnt target genes. The manuscript addresses an important mechanistic detail of the TCF/b-catenin complex, concerning the addition of the ChiLS complex and how the Wnt \"enhanceosome\" may be assembled. The dominant model on TCF/b-catenin mediated transcription is the \"chain of co-activator\" model, which posits that TCF recruits β-catenin that in turn recruits the BCL9 and Pygo complex and other co-activators. The authors have challenged this model through a series studies, including the eLife 2015 paper, and they have argued that the BCL9, Pygo and the new ChiLS complex is preassembled on Wnt enhanceosome to recruit β-catenin. Understanding the mechanism concerning TCF/β-catenin is of general interest and important so the paper in principle is worthy of publication in eLife. However, there are a number of aspects of the work which need to be strengthened to make a compelling case. A few additional experiments should allow the authors to provide the supporting evidence to solidify this model and the authors need to modify the text and discussion around their model where the data are inconsistent. We realize it may take time to conduct the two main experiments suggested but we are willing to allow that time to strengthen this story.

We were pleased that the referees found our study of interest, and stimulated by their challenging of our Wnt enhanceosome model and their generally constructive critique. We thus decided to design and conduct additional experiments to further test our conclusions and proposals, taking up the editors' offer of a substantial extension of our revision deadline. In a nutshell, our additional work includes (1) in-depth analysis of transcriptional Wg responses in imaginal discs from larvae bearing our *lgs* truncation allele, (2) comparative BioID for PYGO2 as well as PYGO2 knock-out by CRISPR/Cas9, and (3) coIP assays to complement our evidence from BioID. We believe that our new results provide compelling support for the enhanceosome model. They also strengthen our insights into the general components of the Wnt enhanceosome that are not dedicated to Wnt signaling, such as Groucho/TLE, CBP/p300 and the subunits of the BAF complex (in particular Osa/ARID1), which broadens the interest of our study.

Inevitably though, our additional work (3 new main figures, with 11 panels total; plus 6 new supplemental figures, with 12 panels total) nearly doubled the data described in our manuscript, and we were thus compelled to recast it as a Research Article. This also allowed us more space to explain more clearly the rationales underlying our approaches, and to outline how our results advance and revise current models of Wnt-dependent transcription switches (including our own; see below). Neither of this was possible in our original submission as a Research Update, because of length restrictions. We hope the referees will agree with us that the new format is appropriate for our revised manuscript.

*The specific points to be addressed are:*

*1) The authors do not discuss some inconsistencies of their data with current models of Wnt signaling. They need to provide a more comprehensive interpretation of their data and how it might be reconciled with their previous studies. If the C-terminal region of Bcl9 proteins functions by binding the repressor TLE, one would expect deleting this region to enhance basal expression of Wnt target genes, rather than reducing their activation by Wnt. Analysis of Wg target gene expression in the lgs^2-8^ mutant might help to clarify this issue.*

In our revised manuscript, we discuss our data in the context of current views of Wnt-dependent transcription switches, adding several references to refer to results published by others on this topic, much of which is consistent with our new evidence (or might be re-interpreted in the light of it). For example, we explain that Groucho/TLE is a bimodal regulator, not only conferring silence on the enhanceosome in the absence of signaling, but also earmarking it (together with other core components) for subsequent Wnt induction (Discussion, fifth paragraph): owing to its multivalent interactions with TCF, ChiLS and the Legless/BCL9 C- terminus, Groucho/TLE assumes the role of a cornerstone within the enhanceosome (see our refined model in new [Figure 7](#fig7){ref-type="fig"}). As such, it may well be crucial for enhanceosome function (presumably by contributing to assembly and/or cohesion of the complex). It seems plausible that removing one of these interactions (e.g. by deleting its binding site in the Legless/BCL9 C-terminus) would compromise enhanceosome function and attenuate Wnt responses. We also point out in our revised manuscript (Discussion, last paragraph) that this positive role of Groucho/TLE within the Wnt enhanceosome is similar to its positive role in estrogen receptor signaling, as recently discovered by the Carroll group (Holmes et al., 2012): these authors showed that TLE1 promotes the interaction of estrogen receptor with chromatin and facilitates its function in stimulating proliferation of breast cancer cells.

Furthermore, we describe our BioID evidence (subsection "β-catenin triggers a Wnt-dependent apposition of the BCL9/B9L C-terminus to TCF") that the CBP/p300 co-activator associates with the Wnt enhanceosome prior to Wnt signaling (revised Figure 4AB, D), possibly via direct interaction with Legless/BCL9, as indicated by RIME (new [Figure 4C](#fig4){ref-type="fig"}).

Although we have not mapped this interaction, the best candidate for the CBP/p300 binding site in Legless/BCL9 is its C-terminus (given that this C-terminus contains three additional conserved sequence blocks, HD4-6, whose putative ligands have yet to be discovered). If so, this would further explain the positive role of this C-terminus, given that CBP/p300 is a well-established co-activator of transcription.

Interestingly, like Groucho/TLE, CBP/p300 is a bimodal regulator, acting activating or repressive depending on context, as shown by the Cadigan group and ourselves (Waltzer et al., 1998; Li et al., 2007). Furthermore, our BioID data indicated that both bimodal regulators are constitutively associated with the enhanceosome ([Figure 4](#fig4){ref-type="fig"}). Indeed, CBP has been found to be active in the absence of Wnt signaling, e.g. towards dTCF (Waltzer et al., 1998), or towards histones, as shown by the Cadigan group (Parker et al., 2008) who detected dCBP-dependent histone acetylation associated with Wg-responsive enhancers prior to Wg-dependent transcription (cited in the fourth paragraph of the Discussion).

Importantly, we have extended our phenotypic analysis of *lgs2-8* mutant larvae and flies (new [Figure 2E, F](#fig2){ref-type="fig"}; new Figure 2---figure supplement 2C), and we have analyzed multiple Wg target genes in different imaginal discs of these mutants, including a Wg-responsive leg enhancer from *dpp (dpp.lacZ*) (new [Figure 2A-D, G](#fig2){ref-type="fig"}; new Figure 2---figure supplement 2A, B). This additional work provides compelling evidence that the deletion of the C-terminus of Legless invariably produces *wg*-like effects (also mimicking attenuated *pygo* function). This supports our conclusion that the C-terminal portion of the protein, downstream of its Pygo-Armadillo adaptor sequences, is essential for promoting transcriptional Wg responses during fly development.

*It is also not clear why the Chip heterozygous phenotype, which looks like a loss of wg function, should be suppressed by removing positively acting components of the complex such as arm and lgs, as well as the negatively acting component gro.*

Genetic interactions caused by heterozygosity of genes (which reduces their expression levels by half, at least in *Drosophila*) are notoriously difficult to interpret. This gets worse if the proteins in question are components of a multiprotein complex, because it is hard to predict how reducing the expression levels of individual components will affect complex assembly, especially if the structure of this complex and its stoichiometry are poorly defined.

Nevertheless, in the revised figure legendof [Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}, we provide what we consider a plausible explanation for the observed genetic interactions. Namely, it is well-established that the wing margin defects caused by halving the dose of *chip* means that this protein is severely limiting in wing discs (as discussed, and also exploited, extensively by the Dale, Cohen and Segal groups and others; see Fiedler et al., 2015).

This haploinsufficiency phenotype caused by *chip*/+ should therefore be exacerbated by lowering expression of its obligatory partner SSDP. It might be ameliorated by lowering the dose of enhanceosome components that, at their normal expression level, potentially sequester the limiting amounts of Chip by direct binding (e.g. Groucho, Pygo and Legless).

*The absence of any Runx protein in the BCL9 and B9L biotinylation assays argues against such a protein being a central part of the Wnt enhanceosome as proposed by Fiedler et al.*

Absolutely, and we now state this explicitly (Discussion, seventh paragraph). We offer the following (in our view plausible) explanation for this finding: namely, the role of RUNX in promoting Wnt enhanceosome function in the *Drosophila* embryo (as uncovered by our study of Wg-responsive embryonic midgut enhancers; Fiedler et al., 2015) is reminiscent of its pioneering functions in other uncommitted cell lineages, e.g. in the hematopoietic system. However, HEK293 cells are epithelial cells, and our data from BioID and Wnt reporter assays clearly show that the Wnt enhanceosome is fully functional in these cells without RUNX (indeed, we could not find any evidence for RUNX protein expression in these cells). A corollary is that RUNX functions in a hit-and-run fashion, to help set up the Wnt enhanceosome on Wnt-responsive enhancers in uncommitted cell lineages; however, once assembled (e.g. in epithelial cells), RUNX is no longer required for enhanceosome- mediated ON/OFF switching. Hit-and-run is a well-established concept in other contexts of transcriptional control during development, e.g. in setting up Polycomb-repressive complexes in the early *Drosophila* embryo.

*The observation that Wnt signaling is necessary for the interaction of Lgs with β-catenin and TCF proteins and does not reduce its association with TLE proteins does not support a model in which the enhanceosome is present at TCF-bound enhancers in the absence of Wnt signaling.*

This was our most intriguing BioID result -- namely the Wnt-inducible labeling of TCF factors by both BCL9-BirA\* and B9L-BirA\*. We proposed in our initial submission that this reflects a β-catenin-dependent increase in proximity between TCF and the BCL9/B9L C- terminus (which bears the BirA\* tag; see also below, point 3). We now provide two new strands of evidence to support this notion: firstly, we use coIP assays to show that the association of BCL9/B9L with TCF is similarly stable before and after Wnt stimulation, like its association with Pygo, while its association with β-catenin depends on Wnt stimulation (new [Figure 4---figure supplement 3A, B](#fig4s3){ref-type="fig"}). Secondly, we have conducted BioID with PYGO2-BirA\* under identical conditions (new [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}), which revealed no new [Figure 4D](#fig4){ref-type="fig"} significant change in the labeling of TCF factors by this bait (), in contrast to the labeling of TCF factors by the BCL9/B9L baits which is strongly Wnt- inducible, especially in the case of B9L-BirA\* (13-30x; [Figure 4A, B](#fig4){ref-type="fig"}). Apart from these factors, the hits identified by PYGO2-BirA\* are remarkably similar to those identified by the BCL9/B9L baits (summarized in new [Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}), showing constitutive labeling of virtually all enhanceosome components. Notable exceptions are β-catenin and CBP/p300 whose labeling is Wnt-dependent or Wnt-stimulated, respectively, as in the case of the BCL9/B9L baits (see above).

As in the case of the BCL9/B9L baits, the list of constitutively labeled components by PYGO2-BirA\* includes TLE3 and TLE1, underscoring our conclusion that these co- repressors remain associated with the Wnt enhanceosome even during Wnt signaling. Although this is against the prevailing view of Groucho/TLE detaching from TCF factors as a result of their binding to β-catenin, but to our knowledge, this has never been explicitly tested (e.g. by ChIP). Unfortunately, the Groucho antiserum previously used for ChIP (e.g. by the Jennings group) and initially produced by Kharchenko et al. (2011) is no longer available. However, this notion of competition between Groucho/TLE and Armadillo/β-catenin was seriously challenged recently by the discovery of Weis and Waterman and co-workers that TLE and β-catenin can bind to TCF simultaneously (Chodaparambil et al., 2014), as we point out in our Introduction.

PYGO2-BirA\* also labels the nuclear co-receptor components, like BCL9-BirA\* and B9L- BirA\*. This strengthens the link between the Wnt enhanceosome and nuclear hormone receptor signaling, as discussed in the last paragraph of the Discussion. In this paragraph, we also cite work by the Carroll group who found a strong association of TLE1 with estrogen receptor-occupied loci in breast cancer cells, and a positive role of TLE1 in promoting the function of this nuclear hormone receptor (Holmes et al., 2012). As mentioned above, this is reminiscent of its role in promoting Wnt enhanceosome function and Wnt responses.

Finally, in the second paragraph of the subsection "β-catenin triggers a Wnt-dependent apposition of the BCL9/B9L C-terminus to TCF", we refer to work by Parker et al. (2002) who provided ChIP-based evidence that, in *Drosophila*, the association of dTCF with target enhancers is increased by Wg signaling. This is not inconsistent with out BioID data from the BCL9/B9L baits which show slightly increased labeling of most Wnt enhanceosome components, although this increase is not seen with the PYGO2 bait. In any case, TCF factors clearly associate with target enhancers in the absence of Wnt signaling in HEK293 cells, as shown by Frietze et al. (2012) (cited in the aforementioned paragraph). Whether or not the binding of β-catenin to Legless/BCL9 and/or TCF results in a stabilization of these interactions will require future testing.

*2) The Authors employed BioID (using BirA\*) followed by mass spectrometry to identify BCL9 (and the related B9L) binding partners (TLE, ChiLS, and nuclear receptor co-activators). They went one step further and combined BioID and spectral counting as a (semi) quantitative measurement for determination of protein interactions with and without Wnt. It is not clear to me whether these methods offer reliable quantification. For example, spectral counts for LDB1 and SSDP in [Figure 3D](#fig3){ref-type="fig"} appear to contradict the IP results in [Figure 3E](#fig3){ref-type="fig"}, in particular with regard to the HD1 deletion mutant. It would be highly desirable that additional approaches can back up these arguments (derived from BioID).*

In the revised manuscript, we state more clearly that coIP assays assess (relatively stable) associations between proteins, while BioID assesses primarily their proximity (even if this reflects weak binding affinities). We have added an introductory paragraph on BioID (subsection "B9L and BCL9 are constitutively associated with the Wnt enhanceosome", first paragraph), explaining how the spectral counts obtained by this approach can be taken as (semi)quantitative measurements of proximity, which can provide insight into the spatial organization of large protein complexes. This was demonstrated in the original Roux et al. (2012) paper by comparing biotin labeling efficiencies of interactors of Laminin A tagged with N-terminal or C-terminal BirA\*. Proximity-dependent labeling efficiencies have since been documented by others, and we cite a compelling example of BioID data obtained by the Stearns group on components of the human centrosomal complex (Firat-Karalar et al., 2014). In the same paragraph, we also mention other factors that can affect the efficiency of biotin labeling by the bait, but these are less relevant for the comparison of hits obtained under different conditions (with or without Wnt), or of hits labeled by different baits under the same conditions (BCL9/B9L versus PYGO2).

Finally, as mentioned above, we have complemented our evidence from BioID with coIP assays, which revealed a relatively stable association between TCF4 and B9L in unstimulated cells, which is only slightly increased upon stimulation (see above; new [Figure 4---figure supplement 3A, B](#fig4s3){ref-type="fig"}).

*One of the key arguments of the authors\' model is that Pygo/BCL9 and associated ChiLS are preassembled on chromatin prior to Wnt stimulation and recruits b-catenin to TCF upon Wnt signaling. The authors should demonstrate this important issue using other techniques, such as CHIP.*

We are unable to conduct ChIP experiments since ChIP-grade antisera for these proteins are not (or no longer) available. Instead, we have conducted coIP experiments, and also comparative BioID labeling by PYGO2-BirA\*, to complement and consolidate our conclusions based on the BCL9/B9L BioID baits (as detailed above).

*3) The NMR results showed that HD3 directly interacts with LDB1/SSDP, and HD3 deletion and W472A mutants reduced BCL9-LDB1 coIP. But HD1 appeared to have a more critical role as its deletion completely abolished BCL9-LDB1 coIP. The authors suggested, reasonably, that HD1 binding to Pygo, which interacts with LDB1, has a critical role in this multivalent interaction. The authors should be able to demonstrate this point directly using Pygo knockdown or knockout (via CRISPR).*

We have done this, by knocking out PYGO2 by CRISPR/Cas9 (new [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). The results (shown in new =Figure 5---figure supplement 3) support our notion of Pygo's critical role in promoting the interaction between LDB1 and BCL9/B9L.
